The creation of a vaccine is a key moment in the fight not only against the epidemic, but also the impending crisis in the global economy. The Russian scientific center “Vector” begins testing prototype vaccines against coronavirus. About it reported Rospotrebnadzor. The first tests will be conducted on sensitive laboratory animals. At this stage, it will be possible to determine whether vaccines are harmless to a living organism. Indeed, studies in a conditional test tube in cell culture cannot simulate the entire complexity of a living organism.
According to experts, in vitro it is impossible to test the ability of a vaccine to induce an immune response that can protect sensitive animals from being infected with a deadly virus. At this stage, the researchers find out the effective dose of the vaccine, the frequency of its administration, the method of vaccination.
Russian scientists are very optimistic. They expect that the introduction of the vaccine in case of successful clinical trials will be possible in the fourth quarter of 2020.
What is the situation with the search for a vaccine in the world?
In the three months since the spread of the virus, all the advanced countries of the world have entered the sprint race to develop a vaccine. International cooperation has been established not only at the state, but also at the private level.
The vaccine is crucial in the economic crisis looming after the pandemic, which could shake the global economy. A winner in the vaccine development race will be a potential winner in the fight against the economic and geostrategic effects of the crisis, The New York Times said. This is not about scientific awards and patents, but about national security issues.
Clinical trials (in humans) of vaccines may begin as early as April. Developments are actively conducted in the USA, China, Europe. And the first successful development will be in serious shortage.
Here are just a few companies and states that focus on vaccine production.
The government-run Canadian Institute for Medical Research is partly funding the development of an experimental herbal vaccine by Medicago, which is based on a virus-like particle grown in the Nicotiana benthamiana plant. It is used in pharmaceuticals to create monoclonal antibodies and other recombinant proteins.
The American company Altimmune received the digital genetic sequence SARS-CoV-2 at the end of January. The development and synthesis of the vaccine took about four weeks. The company is waiting for the necessary material to begin testing the prototype on animals in late March or early April.
The U.S. National Institute of Allergy and Infectious Diseases March 16 began administering the mRNA-1273 vaccine to 45 volunteers aged 18 to 55. This phase will last about 6 weeks. The director of the institute notes that the first phase of the tests began record fast.
Generex has entered into a vaccine development contract with a Chinese consortium, which includes the CTEX State Technology Exchange, the Shandong Biological Institute of the Chinese Academy of Sciences, the Beijing Investment Fund and others. For each dose of vaccine produced, Generex will receive a 20% royalty charge.